Lung Cancer Trial, Recruiting (NCT07190677)

Lung Cancer Trial, Recruiting NCT07190677 Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia Condition: Lung Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT07190677 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lung Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with advanced (stage IV) or returned (recurrent) non-small cell lung cancer (NSCLC), confirmed through laboratory testing of tissue or cell samples
People whose doctor has already decided, separately from this study, to start them on a specific combination treatment (nivolumab plus ipilimumab, along with 2 cycles of platinum-based chemotherapy) as their first treatment for NSCLC, in line with Italian approved prescribing guidelines, and whose tumour does not have certain specific genetic changes (known as EGFR mutation or ALK translocation)
People who are at least 18 years old at the time their doctor made the treatment decision
People who have given written consent to take part in the study

Who may not be able to join:

People who currently have another type of cancer (other than NSCLC) that requires active treatment
People who have previously been treated with nivolumab and/or ipilimumab
People who are already taking part in another interventional clinical trial for their advanced or recurrent NSCLC

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 6 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 0382501433

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07190677

Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia

Phase: Not Applicable

Status: Recruiting

Condition: Lung Cancer

Trial contact: 0382501433

More information: https://clinicaltrials.gov/study/NCT07190677

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with advanced (stage IV) or returned (recurrent) non-small cell lung cancer (NSCLC), confirmed through laboratory testing of tissue or cell samples
People whose doctor has already decided, separately from this study, to start them on a specific combination treatment (nivolumab plus ipilimumab, along with 2 cycles of platinum-based chemotherapy) as their first treatment for NSCLC, in line with Italian approved prescribing guidelines, and whose tumour does not have certain specific genetic changes (known as EGFR mutation or ALK translocation)
People who are at least 18 years old at the time their doctor made the treatment decision
People who have given written consent to take part in the study

Who may not be able to join:

People who currently have another type of cancer (other than NSCLC) that requires active treatment
People who have previously been treated with nivolumab and/or ipilimumab
People who are already taking part in another interventional clinical trial for their advanced or recurrent NSCLC

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 6 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia

Registry

ClinicalTrials.gov

Start date

17 January 2025

Est. completion

31 December 2025

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

to estimate OS and PFS

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov